The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling Figure S1 : Effects of TIMP-1 on CFU-GM/BFU-E growth from AML-derived cells. Circulating leukemic blasts were isolated from AML patients and cultured in semisolid medium in the presence of TIMP-1. After 14 days, the total CFU-L output was assessed as above described. (A) The CFU-GM growth of the AML-derived leukemic cells was significantly stimulated by TIMP-1 (100 ng/ml, **p ≤ 0.01) (n = 12). The mean number of CFU-GM colonies in untreated (0 ng/ml) and treated (100 ng/ml) AML samples was 17.5 ± 5.5 vs 28 ± 9.6, respectively. (B) The growth of BFU-E showed the same pattern displayed by CFU-GM but not significantly (n = 5). The mean number of BFU-E colonies in untreated (0 ng/ml) and treated (100 ng/ml) AML samples was 7.4 ± 4.49 vs 11 ± 4.7, respectively. The results are expressed as growth fold change versus untreated control samples. Figure S2 : Effects of TIMP-1 on survival in 14 AML patients. AML cells from 14 patients were in vitro treated for 2 days with TIMP-1 and the percentage of cell viability was assessed after AnnexinV/PI staining, as described in methods. For each patient the percentage of apoptotic cells was reported in the absence (black columns) or in presence of TIMP-1 (grey columns).
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